VIRAL IMMUNOLOGY病毒免疫学
VIRAL IMMUNOLOGY(英文缩写 VIRAL IMMUNOL),ISSN 0882-8245,eISSN 1557-8976,中文译名:病毒免疫学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.175 | Q4 |
| 2022 | 2.200 | Q4 |
| 2023 | 1.500 | Q4 |
| 2024 | 1.200 | Q4 |
| 2025 | 1.500 | Q4 |
VIRAL IMMUNOLOGY 最新收录文献
-
1. Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca.
PMID:日期:2026-10-01The diversity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine platforms and widespread natural exposure have created a complex landscape of humoral immunity requiring detailed characterization. Here, we compare nucleocapsid (N)- and spike (S)-specific antibody responses in sera from infected humans (IH) during the first pandemic wave (April-August 2020) and in vaccine recipients (Sinopharm, Sinovac, or AstraZeneca) using commercial ELISA kits. Among naturally IH, the IgG-positivity rate was higher for N (80.9%) than S (42.8%), with significantly elevated N-specific IgG levels compared to prepandemic controls (-value <0.05), while IgM responses showed no significant differences. Strong positive correlations were observed between S- and N-specific antibody responses, particularly for IgG and its subclasses. Vaccinated cohorts exhibited high IgG positivity rate (83-100%) against both antigens with low IgM levels, and overall IgG and subclass responses were significantly elevated relative to pre-pandemic controls (-value <0.05), with consistently strong inter-antigen correlations across groups. Overall, natural infection induces a coordinated humoral response biased toward the nucleocapsid antigen, supporting its utility as a marker of recent infection, whereas vaccination elicits a robust multi-subclass antibody response with platform-dependent differences in antigen recognition and subclass distribution.
-
2. Causal Impact of Blood Cell Traits on the Risk of Herpes Zoster: A Two-Sample Mendelian Randomization Study Based on Exogenous Stimulation Data.
PMID:日期:2026-10-01Herpes zoster (HZ) is a common neurotropic infectious disease caused by the reactivation of varicella-zoster virus (VZV), primarily triggered by declining host immune function. While circulating immune cells play key roles in antiviral defense, the causal contributions of distinct blood cell functional phenotypes to HZ risk remain unclear.To investigate potential causal associations between genetically predicted blood cell functional traits under stimulation and the risk of HZ using a two-sample Mendelian randomization (MR) framework.We employed genome-wide association analysis summary statistics of 91 stimulation-induced blood cell traits published in 2024 as exposures, and HZ outcome data from the FinnGen R12 release (7,132 cases and 480,316 controls). The inverse variance weighted method was used for primary causal inference, complemented by alternative MR approaches and sensitivity analyses to assess robustness. No formal multiple testing correction was applied due to a single significant result.Among 85 eligible traits, the forward scatter standard deviation (FSC-SD) of red blood cells under nigericin stimulation was significantly associated with increased HZ risk (OR = 1.13, 95% CI: 1.06-1.20, = 1.02 × 10). No other traits reached nominal significance. Sensitivity analyses revealed no evidence of horizontal pleiotropy or heterogeneity.This study provides novel genetic evidence that nigericin-induced red blood cell membrane stress responses, operating through NLRP3-dependent inflammatory cascades, are causally linked to VZV reactivation susceptibility. The nigericin-stimulated red blood cells FSC-SD phenotype may serve as a functional biomarker for viral reactivation risk stratification and individualized immune monitoring.
-
3. Utilization of Similar Epitopes to Develop Viral Vaccines that Produce Lifelong Immunity.
PMID:日期:2026-10-01The half-life (HL) of specific antibodies produced by the human body against various viruses varies from about 4 months to 11,000 years. Due to their short half-lives, multiple-dose vaccinations and annual revaccination are usually required for most viruses, which cause a large economic burden, especially in developing countries with limited storage of vaccines. Protein assemblies with a high degree of repetitiveness and organization are known to induce strong and long-lasting immune responses. However, the detailed quantitative law is still unknown. Through epitope analysis of representative viruses, we found that the longevity of immunological memory may be correlated with the number of epitopes with similar sequences (EWSS). Accordingly, a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with 4.5-times higher antibody titers and over 100 months of HL was developed in a rabbit model. The decay pattern of antibodies against each epitope or the entire SARS-CoV-2 spike protein was roughly correlated with the number of EWSS in immunization treatments, that is, for every additional EWSS, the HL of the antibody would be doubled. This study also discusses improvement measures for vaccines against other viruses.
-
4. {"_":"Genetic Variants of NRAMP1 and Hepcidin () in Cancer Patients Infected with Human Herpesvirus-6.","i":["HAMP"]}
PMID:日期:2026-09-17Human herpesvirus-6 (HHV-6) is involved in immune modulation and contributes to cancer development through interactions with host genetic factors. Hepcidin () and NRAMP1 genes play essential roles in iron metabolism and innate immunity, yet their polymorphisms remain poorly investigated in HHV-6-associated cancers. This study investigated the association between and NRAMP1 gene polymorphisms and HHV-6 infection in 40 confirmed HHV-6-positive cancer patients compared with 40 non-cancer, HHV-6-negative controls. Genomic DNA was extracted and verified by agarose gel electrophoresis. Hepcidin polymorphisms were analyzed using Tetra-ARMS PCR, while NRAMP1 (3'UTR) polymorphism was detected by PCR-RFLP. Cancer patients exhibited wild-type, mutant, and heterozygous hepcidin genotypes, whereas controls predominantly showed the wild-type genotype. Although allele frequency analysis revealed no statistically significant difference for the G and TG alleles between groups ( = 0.23), the hepcidin A allele (521 bp) was more frequent among cancer patients, suggesting a possible association with increased cancer susceptibility (odds ratio = 2.111). For NRAMP1, three genotypic patterns were identified (TG-/TG-, TG+/TG+, and TG-/TG+), and while no significant between-group difference was detected ( = 0.23), the TG+ allele demonstrated a potential two-fold increased cancer risk among carriers. These findings suggest that specific allelic variants-particularly the hepcidin A allele and NRAMP1 TG+ allele-may contribute to cancer susceptibility in HHV-6-infected individuals, highlighting a possible genetic-viral interaction that influences immune and iron-regulatory pathways in cancer development.
-
5. Reovirus Reassortants Reveal Context-Dependent Oncolytic Phenotypes Across Epithelial Cancer Cell Lines.
PMID:日期:2026-09-01Mammalian reoviruses are promising oncolytic agents, but most preclinical and clinical work has focused on the type 3 Dearing (T3D) prototype, potentially underestimating the therapeutic relevance of broader reovirus genetic diversity. Because reoviruses possess a segmented double-stranded RNA genome, reassortment can generate progeny with novel combinations of traits influencing infectivity, replication, and cytotoxicity. Here, we evaluated a panel of previously generated T1L × T3D reassortants and recombinant reoviruses across three epithelial tumor models: A549 lung adenocarcinoma and the oral squamous carcinoma cell lines OECM-1 and CAL-27. Across all three models, the tested viruses displayed marked cell line-dependent heterogeneity in both cytotoxicity and infectivity. Several reassortants reduced viability more effectively than the parental T1L and T3D strains in one or more cell lines, and DB62 emerged as the most broadly active candidate across the panel. Infectivity and cytotoxicity overlapped only partially, indicating that efficient infection alone does not fully predict oncolytic potency. Together, these findings show that reassortment can generate reoviruses with enhanced or selective activity across epithelial tumor contexts and support future studies examining how segment-dependent differences in interferon antagonism, entry, and cell death shape oncolytic potency.
-
6. Screening and Characterization of Nanobody Against the Emerging Dairy Cattle H5N1 Influenza Virus.
PMID:日期:2026-09-01The ongoing spillover of highly pathogenic avian influenza H5N1 virus into mammalian species, including recent outbreaks in dairy cattle, underscores an urgent need for broadly effective therapeutics. Nanobody, the variable domain of heavy chain-only antibody, offers unique advantages for viral neutralization due to its small size, stability, and accessibility to cryptic epitopes.In this study, we isolated a human nanobody, nAb35, targeting the hemagglutinin of the dairy cattle H5N1 virus A/Texas/37/2024 (clade 2.3.4.4b) via phage display of a human nanobody library. After three rounds of panning against the recombinant H5 ectodomain, a dominant clone (nAb35) was highly enriched. Then nAb35 was fused with a human IgG1 Fc fragment and expressed as a bivalent dimer.Biochemical characterization demonstrated that nAb35 specifically binds to H5 under both denaturing and native conditions and recognizes a linear epitope accessible on H5 expressed on the cell surface. neutralization assays using H5 pseudovirus showed that nAb35 inhibited viral entry with a half-maximal effective concentration of approximately 10 μg/mL, as determined by both luciferase reporter and immunofluorescence assays.These findings identify nAb35 as a promising candidate for further therapeutic development against emerging H5N1 virus.
-
7. Immunoinformatics-Driven Design of a Multiepitope Vaccine for Rustrela Virus-Induced Neurological Diseases: A New Frontier in Encephalitis and Meningoencephalitis Prevention.
PMID:日期:2026-09-01Rustrela virus (Rubivirus strelense) is a single-stranded, non-segmented RNA virus that causes brain diseases in animals, especially encephalitis and meningoencephalitis. Its rapidly mutating RNA genome complicates control, making a vaccine imperative. Immunoinformatics approaches were employed to make the polyepitope vaccine (PEV) for RuV control. Epitopes for cytotoxic T lymphocytes (CTL), helper T lymphocytes (HTL), and B cells were made from most immunogenic parts i.e., E1, E2, and capsid structural proteins of RuV. Epitopes that were antigenic, not allergic, IFN simulators, and not toxic were selected. This led to the selection of 6 CTL, 6 HTL, and 13 B cell epitopes, which were then used to construct the PEV with appropriate linkers and CTB as an adjuvant for immunological modulation. The physiochemical analyses demonstrated that the PEV was safe, stable, hydrophilic, and soluble. The secondary structure prediction has indicated mostly coiled and alpha helix in the PEV. The 3D scans revealed a solid and stable structure. The interactions and stability between the vaccine, TLR3, TLR4, and TLR7 were revealed by molecular docking. The vaccine candidate's minimal deformability and high stability were verified by molecular dynamics modeling. The developed PEV vaccine demonstrated a strong immunological response in immune simulation. RuV-PEV is predicted to be efficiently produced in following codon optimization and vector cloning. It elicited strong antigen-specific humoral and cellular responses, indicating promise as a Rustrela virus vaccine. Its precise effectiveness, safety, and immunogenicity profile may be confirmed by further experimental validations.
-
8. Syncytia Formation in the Pathogenesis of SARS-CoV-2 Infection: Lessons from Viral Infections.
PMID:日期:2026-08-01It is widely known that numerous enveloped viruses can produce multinucleated cells (syncytia) as a result of viral entry-related membrane fusion events. By protecting the virus from the host's immune reaction, these syncytia are thought to promote viral reproduction. Syncytia are collections of merged cells. A viral spike protein (S) on the surface of an infected cell interacts with receptors on nearby cells to cause the syncytia response. The innate immune system's response to viruses affects how syncytia form. Some interferon-stimulated genes change the membrane in a way that reduces the likelihood of fusion. The severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus is quickly changing; also, several mutations occurred in its S protein. Individually and together, the Alpha, Beta, Gamma, and Delta variants carry mutations that significantly affect S function and syncytia formation. The function of syncytia in newly emerging variant diseases is still unknown, though. Syncytia could cause disease through promoting viral transmission, cytopathicity, immunological evasion, and inflammatory responses. The SARS-CoV-2 S protein variations include several changes that improve receptor interactions, fusogenicity, and antibody reactivity. A wide range of clinical symptoms, including moderate febrile sickness, severe respiratory distress, and occasionally deadly lung damage, can be brought on by an infection with SARS-CoV-2. Several of these lung illnesses (MERS-CoV) are linked to both the Middle East Respiratory Syndrome (MERS) and the severe acute respiratory syndrome coronavirus (SARS-CoV). Compared to acute respiratory syndromes, the lung thrombosis brought on by Coronavirus disease 2019 (COVID-19) is incredibly severe. In this review we focused on innate immunological elements that prevent syncytia from forming and the molecular triggers of S-mediated fusion.
-
9. Effect of Pentoxifylline on Inflammatory Markers in COVID-19: A Meta-Analysis of Randomized Controlled Trials.
PMID:日期:2026-08-01The hyperinflammatory response in COVID-19 is a major factor contributing to morbidity. Pentoxifylline, a methylxanthine derivative, has immunomodulatory properties, but its effects on inflammatory markers in COVID-19 remain unclear. This meta-analysis aims to evaluate the efficacy of pentoxifylline supplementation on CRP and interleukin-6 (IL-6) levels in these patients. A systematic search was conducted across multiple databases for randomized controlled trials (RCTs) published up to September 2025. Four RCTs, including 178 cases and 321 controls for CRP, and two RCTs, including 70 cases and 70 controls for IL-6, were included. Two reviewers independently performed data extraction and assessed the risk of bias using the Cochrane tool. Pooled standardized mean differences (SMDs) were calculated using a random-effects model. Heterogeneity was analyzed through meta-regression, and the conclusiveness of the evidence was evaluated using Trial Sequential Analysis (TSA). Pentoxifylline did not significantly reduce C-reactive protein (CRP) levels compared to the control group (SMD = -0.89; 95% CI: -1.85 to 0.07; = 0.07). However, substantial heterogeneity was noted across the studies ( 95.3%). Similarly, a nonsignificant trend toward reduction was observed for IL-6 (SMD = -0.22; 95% CI: -0.96 to 0.52; = 0.55), accompanied by significant heterogeneity ( 79.1%). Given the limited number of studies included, the results are inherently fragile, and one additional trial could substantially shift the pooled estimate. Meta-regression analysis indicated that patient age and publication year did not account for the heterogeneity, although there was a nonsignificant trend suggesting that a longer treatment duration might be associated with greater CRP reduction. TSA for CRP showed that cumulative evidence suggested futility and a lack of meaningful effect, confirming a significant lack of effect. The included studies generally had a low risk of attrition and reporting bias. Current evidence does not support the use of pentoxifylline for significantly reducing CRP or IL-6 levels in COVID-19 patients. The findings regarding CRP are considered conclusive, but the limited number of studies suggests that further trials on this outcome may alter this conclusion.
-
10. A Robust Defense Against IPNV and VHSV by Designing Revolutionary Multi-Epitope Vaccine Utilizing Immunoinformatics Approaches.
PMID:日期:2026-08-01In the intricate world of aquatic ecosystems, infectious pancreatic necrosis virus (IPNV) and viral hemorrhagic septicemia virus (VHSV) emerge as formidable threats to marine life, posing diverse diseases that reverberate through shared host species (Salmon, trout fishes). The coexistence of these viruses amplifies health risks, compelling the pursuit of inventive intervention strategies. Recognizing the urgency, a current and optimistic initiative strives to craft a revolutionary combined vaccine, offering protection against both IPNV and VHSV. This innovative endeavor, driven by an immunoinformatics approach, identifies immune-dominant epitopes from CadB and LamB proteins, ensuring the final vaccine's immunogenicity, non-allergenicity, and enhanced solubility. Molecular dynamics simulations validate its binding stability and structural integrity. In a pivotal move, codon optimization using K12 as a model result in an ideal guanine-cytosine content and a higher Codon Adaptation Index value, seamlessly integrating into the cloning vector pET2+ (a). In essence, our outcomes underscore the potential of this proposed peptide vaccine to elicit a robust immune response against both IHNV and VHSV, marking a breakthrough in the holistic management of infectious diseases in aquatic environments.